Is nicotine protective against Parkinson's disease? An experimental analysis

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 7, 2012, Pages 897-906

  García Montes, José Rubén ^a   Boronat García, Alejandra ^a   López Colomé, Ana María ^a   Bargas, José ^a   Guerra Crespo, Magdalena ^a   Drucker Colín, René ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Basal ganglia; Chronic nicotine; Dopamine receptor; Inter neurons; Parkinson's disease; Striatum

Indexed keywords

AMPHETAMINE; DOPAMINE RECEPTOR; NICOTINE; PARVALBUMIN; PROTEIN C FOS; SOMATOSTATIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICRODIALYSIS; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SPIKE WAVE;

AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; INTERNEURONS; MALE; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NICOTINE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA;

EID: 84873186058     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311201070897     Document Type: Article

References (45)

1. Harris, M.K.; Shneyder, N.; Borazanci, A.; Korniychuk, E.; Kelley, R.E.; Minagar, A. Movement disorders. Med. Clin. North Am., 2009, 93, 371-388.
2. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res., 2004, 318, 121-134.
3. Gorell, J.M.; Rybicki, B.A.; Johnson, C.C.; Peterson, E.L. Smoking and Parkinson's disease: a dose-response relationship. Neurology, 1999, 52, 115-119.
4. Hernan, M.A.; Zhang, S.M.; Rueda-deCastro, A.M.; Colditz, G.A.; Speizer, F. E; Ascherio, A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann. Neurol., 2001, 50, 780-786.
5. Driver, J.A.; Logroscino, G.; Gaziano, J.M.; Kurth, T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology, 2009, 72, 432-438.
6. Villafane, G.; Cesaro, P.; Rialland, A.; Baloul, S.; Azimi, S.; Bourdet, C.; Le, Houezec, J.; Macquin-Mavier, I.; Maison, P. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur. J. Neurol., 2007, 14, 1313-1316.
7. Fagerstrom, K.O.; Pomerleau, O.; Giordani, B.; Stelson, F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl.), 1994, 116, 117-119.
8. Ryan, R.E.; Ross, S.A.; Drago, J.; Loiacono, R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol., 2001, 132, 1650-1656.
9. Costa, G.; Abin-Carriquiry, J.A.; Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res., 2001, 888, 336-342.
10. Quik, M.; Chen, L.; Parameswaran, N.; Xie, X.; Langston, J.W.; McCallum, S.E. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci., 2006, 26, 4681-4689.
11. Bordia, T.; Campos, C.; Huang, L.; Quik, M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther., 2008, 327, 239-247.
12. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des., 2006, 12, 407-428.
13. Dehorter, N.; Guigoni, C.; Lopez, C.; Hirsch, J.; Eusebio, A.; Ben-Ari, Y.; Hammond, C. Dopamine-deprived striatal GABAergic interneurons burst and generate repetitive gigantic IPSCs in medium spiny neurons. J. Neurosci., 2009, 29, 7776-7787.
14. Gittis, A.H.; Nelson, A.B.; Thwin, M.T.; Palop, J.J.; Kreitzer, A.C. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J. Neurosci., 2010, 30, 2223-2234.
15. Xiao, C.; Nashmi, R.; McKinney, S.; Cai, H.; McIntosh, J.M.; Lester, H.A. Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. J. Neurosci., 2009, 29, 12428-12439.
16. Gittis, A.H.; Hang, G.B.; LaDow, E.S.; Shoenfeld, L.R.; Atallah, B.V.; Finkbeiner, S.; Kreitzer, A.C. Rapid target-specific remodeling of fastspiking inhibitory circuits after loss of dopamine. Neuron, 2011, 71, 858-868.
17. Gittis, A.H.; Leventhal, D.K.; Fensterheim, B.A.; Pettibone, J.R.; Berke, J.D.; Kreitzer, A.C. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J. Neurosci., 2011, 31, 15727-15731.
18. Benowitz, N.L.; Dains, K.M.; Dempsey, D.; Yu, L.; Jacob, P., 3rd Estimation of nicotine dose after low-level exposure using plasma and urine nicotine metabolites. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 1160-1166.
19. Le Houezec, J.; Martin, C.; Cohen, C.; Molimard, R. Failure of behavioral dependence induction and oral nicotine bioavailability in rats. Physiol. Behav., 1989, 45, 103-108.
20. Rabbaa-Khabbaz, L.; Abi Daoud, R.; Karam-Sarkis, D. A simple, sensitive, and rapid method for the determination of cotinine in urine by high-performance liquid chromatography with UV detection. J. Chromatogr. Sci., 2006, 44, 535-538.
21. Dunnett, S.B.; Bjorklund, A.; Stenevi, U.; Iversen, S.D. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. II. Bilateral lesions. Brain Res., 1981, 229, 457-470.
22. Zetterstrom, T.; Sharp, T.; Collin, A.K.; Ungerstedt, U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol., 1988, 148, 327-334.
23. Ungerstedt, U.; Arbuthnott, G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res., 1970, 24, 485-493.
24. Duran-Vazquez, A.; Drucker-Colin, R. Differential role of dopamine receptors on motor asymmetries of nigro-striatal lesioned animals that are REM sleep deprived. Brain Res., 1997, 744, 171-174.
25. Collins, T.J. ImageJ for microscopy. Biotechniques, 2007, 43, 25-30.
26. Vine, M.F.; Hulka, B.S.; Margolin, B.H.; Truong, Y.K.; Hu, P.C.; Schramm, M.M.; Griffith, J.D.; McCann, M.; Everson, R.B. Cotinine concentrations in semen, urine, and blood of smokers and nonsmokers. Am. J. Public Health, 1993, 83, 1335-1338.
27. Maggio, R.; Riva, M.; Vaglini, F.; Fornai, F.; Molteni, R.; Armogida, M.; Racagni, G.; Corsini, G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem., 1998, 71, 2439-2446.
28. Kaneko, S.; Maeda, T.; Kume, T.; Kochiyama, H.; Akaike, A.; Shimohama, S.; Kimura, J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res., 1997, 765, 135-140.
29. Meshul, C.K.; Kamel, D.; Moore, C.; Kay, T.S.; Krentz, L. Nicotine alters striatal glutamate function and decreases the apomorphineinduced contralateral rotations in 6-OHDA-lesioned rats. Exp. Neurol., 2002, 175, 257-274.
30. Jaidar, O.; Carrillo-Reid, L.; Hernandez, A.; Drucker-Colin, R.; Bargas, J.; Hernández-Cruz, A. Dynamics of the Parkinsonian striatal microcircuit: entrainment into a dominant network state. J. Neurosci., 2010, 30, 11326-11336.
31. Sgambato, V.; Maurice, N.; Besson, M.J.; Thierry, A.M.; Deniau, J.M. Effect of a functional impairment of corticostriatal transmission on cortically evoked expression of c-Fos and zif 268 in the rat basal ganglia. Neuroscience, 1999, 93, 1313-1321.
32. Sagar, S.M.; Sharp, F.R.; Curran, T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science, 1988, 240, 1328-1331.
33. Wen, L.; Wang, H.; Tanimoto, S.; Egawa, R.; Matsuzaka, Y.; Ishizuka, T.; Yawo, H. Opto-current-clamp actuation of cortical neurons using a strategically designed channelrhodopsin. PLoS One, 5, e12893.
34. Schoenenberger, P.; Gerosa, D.; Oertner, T.G. Temporal control of immediate early gene induction by light. PLoS One, 2009, 4, e8185.
35. Quarta, D.; Ciruela, F.; Patkar, K.; Borycz, J.; Solinas, M.; Lluis, C.; Franco, R.; Wise, R.A.; Goldberg, S.R.; Hope, B.T.; Woods, A.S.; Ferré, S. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology, 2007, 32, 35-42.
36. Sulzer, D., 2011 How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron, 69, 628-649.
37. Gregorio, M.L.; Wietzikoski, E.C.; Ferro, M.M.; Silveira, J.L.; Vital, M.A.; Da Cunha, C. Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats. Neurotox. Res., 2009, 15, 359-366.
38. Factor, S.A. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology, 2004, 62, S12-S17.
39. Hebb, M.O.; Robertson, H.A. Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases. J. Comp. Neurol., 1999, 410, 99-114.
40. Taverna, S.; Ilijic, E.; Surmeier, D.J. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J. Neurosci., 2008, 28, 5504-5512.
41. Kravitz, A.V.; Freeze, B.S.; Parker, P.R.; Kay, K.; Thwin, M.T.; Deisseroth, K.; Kreitzer, A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature, 2010, 466, 622-626.
42. Albin, R.L.; Young, A.B.; Penney, J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci., 1989, 12, 366-375.
43. Carrillo-Reid, L.; Tecuapetla, F.; Ibanez-Sandoval, O.; Hernandez-Cruz, A.; Galarraga, E.; Bargas, J. Activation of the cholinergic system endows compositional properties to striatal cell assemblies. J. Neurophysiol., 2009, 101, 737-749.
44. Carrillo-Reid, L.; Hernandez-Lopez, S.; Tapia, D.; Galarraga, E.; Bargas, J. Dopaminergic modulation of the striatal microcircuit: receptor-specific configuration of cell assemblies. J. Neurosci., 2011, 31, 14972-14983.
45. Morens, D.M.; Grandinetti, A.; Davis, J.W.; Ross, G.W.; White, L.R.; Reed, D. Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Am. J. Epidemiol., 1996, 144, 400-404.